MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Monopar Therapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$71.47+2.20 (+3.18%)
Close on Oct 19, 2026
- Market cap
- $610.53M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.7%
6M of 7M shares
Institutional holders
96
30 new, 14 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 25 sales
Net sold $4.41M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Kolchinsky | 667,632 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Atchinson | 599,195 | 9.86% | 13G (passive) | Dec 31, 2024 |
| AstraZeneca PLC | 522,667 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Phillip Gross | 424,195 | 6.23% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 1,287,368 | 19.50% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MNPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 1,312,129 | 19.55% | $121.70M | New | 0.05% |
| Ra Capital Management, L.P. | 667,207 | 9.94% | $61.78M | – | 0.54% |
| BlackRock, Inc. | 348,819 | 5.20% | $32.30M | +32,252 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 323,745 | 4.82% | $29.98M | – | 0.31% |
| Saturn V Capital Management LP | 311,976 | 4.65% | $28.89M | −33,650 | 4.14% |
| Siren, L.L.C. | 270,118 | 4.02% | $25.01M | – | 0.51% |
| ADAR1 Capital Management, LLC | 217,595 | 3.24% | $20.15M | −46,683 | 0.92% |
| Polar Capital Holdings Plc | 214,469 | 3.20% | $19.86M | −12,057 | 0.05% |
| Vanguard Capital Management LLC | 209,711 | 3.12% | $19.42M | −8,752 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 209,195 | 3.12% | $19.37M | −100,000 | 0.03% |
| TCG Crossover Management, LLC | 203,327 | 3.03% | $18.83M | +71,224 | 0.45% |
| Wellington Management Group Llp | 158,437 | 2.36% | $14.67M | −15,905 | 0.00% |
| Orbimed Advisors LLC | 157,423 | 2.35% | $14.58M | New | 0.27% |
| Candriam S.C.A. | 143,339 | 2.14% | $13.26M | New | 0.06% |
| Balyasny Asset Management L.P. | 134,543 | 2.00% | $12.46M | −1,900 | 0.02% |
| Geode Capital Management, LLC | 112,578 | 1.68% | $10.43M | +12,660 | 0.00% |
| Alyeska Investment Group, L.P. | 100,000 | 1.49% | $9.26M | – | 0.02% |
| State Street Corp | 92,551 | 1.38% | $8.57M | +4,196 | 0.00% |
| Vivo Capital, LLC | 90,500 | 1.35% | $8.38M | – | 0.77% |
| Driehaus Capital Management LLC | 84,040 | 1.25% | $7.78M | +50,884 | 0.05% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 6M | 92.7% | 30 / 32 | 24 / 14 | 2M | 1M |
| Q1 2026 | 82 | 6M | 92.9% | 20 / 33 | 18 / 11 | 2M | 1M |
| Q4 2025 | 74 | 6M | 82.3% | 23 / 32 | 10 / 5 | 1M | 0M |
| Q3 2025 | 56 | 4M | 64.6% | 16 / 19 | 14 / 3 | 1M | 0M |
| Q2 2025 | 43 | 3M | 47.3% | 19 / 15 | 4 / 11 | 0M | 0M |
| Q1 2025 | 35 | 3M | 43.0% | 18 / 6 | 5 / 1 | 0M | 0M |
| Q4 2024 | 18 | 3M | 38.4% | 12 / 3 | 1 / 0 | 3M | 0M |
| Q3 2024 | 6 | 0M | 0.2% | 6 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MNPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 159,786 | 2.38% | $14.79M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 118,700 | 1.77% | $10.99M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 49,332 | 0.73% | $5.35M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 44,311 | 0.66% | $4.10M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 31,751 | 0.47% | $2.94M | 0.02% | Jun 30, 2026 |
| Neuberger Small Cap Growth Fund | 25,313 | 0.38% | $1.65M | 0.24% | May 31, 2026 |
| BNY Mellon Small/Mid Cap Growth Fund | 23,890 | 0.36% | $2.21M | 0.25% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 22,728 | 0.34% | $1.48M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 20,497 | 0.31% | $1.33M | 0.00% | May 31, 2026 |
| Vanguard U.S. Momentum Factor ETF | 19,767 | 0.29% | $1.29M | 0.07% | May 31, 2026 |
| iShares Micro-Cap ETF | 15,148 | 0.23% | $1.40M | 0.09% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 10,953 | 0.16% | $1.19M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 10,465 | 0.16% | $968.95K | 0.01% | Jun 30, 2026 |
| Master Small Cap Index Series | 7,737 | 0.12% | $716.37K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 7,192 | 0.11% | $467.77K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Chandler Robinson | Chief Executive Officer, Director | 191,138 | 2.85% | Sep 28, 2026 |
| Pharma LLC Tactic | Chief Executive Officer, Director, 10% owner | 4,383,299 | 65.30% | Sep 26, 2025 |
| Quan Anh Vu | Chief Financial Officer | 2,221 | 0.03% | Jul 2, 2026 |
| Andrew Cittadine | Chief Operating Officer | 57,923 | 0.86% | Jul 2, 2026 |
| Susan Rodriguez | CCSO | – | – | Mar 4, 2026 |
| Karthik Radhakrishnan | Chief Financial Officer | 1,550 | 0.02% | Oct 30, 2024 |
| Raymond Anderson | Director | 5,373 | 0.08% | Aug 28, 2026 |
| Kim R. Tsuchimoto | Director | 12,678 | 0.19% | Aug 28, 2026 |
| Nicole Sweeny | Director | – | – | Jun 30, 2026 |
| Arthur J. Klausner | Director | 3,064,156 | 45.65% | Dec 19, 2025 |
| Lavina Talukdar | Director | 14,001 | 0.21% | Dec 8, 2025 |
| Christopher M. Starr | Director | 31,853 | 0.47% | Dec 8, 2025 |
| Patrice Rioux | – | 5,066 | 0.08% | Aug 27, 2026 |
| Diane Hendricks | 10% owner | 567,580 | 8.46% | Dec 17, 2025 |
| Thomas V. O'Halloran | – | 4,402,940 | 65.60% | Sep 26, 2025 |
| Andrew Paul Mazar | – | 188,792 | 2.81% | Sep 26, 2025 |
| Michael J. Brown | – | 4,933,528 | 73.50% | Sep 26, 2025 |
| LLC TacticGem | 10% owner | 0 | – | Dec 17, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +15,000 | $14.00 | $210.00K | 128,323 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Option exercise | +14,056 | $30.00 | $421.68K | 113,323 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −10,450 | $87.15 | $910.72K | 117,873 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −9,638 | $87.96 | $847.76K | 108,235 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −8,368 | $88.97 | $744.50K | 99,867 |
| Chandler Robinson Chief Executive Officer, Director | Sep 24, 2026 | Sale(10b5-1 plan) | −600 | $89.79 | $53.87K | 99,267 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −1,098 | $111.84 | $122.80K | 1,192 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Option exercise | +2,055 | $30.00 | $61.65K | 2,055 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Option exercise | +2,035 | $14.00 | $28.49K | 4,090 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −485 | $108.83 | $52.78K | 3,605 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −615 | $109.56 | $67.38K | 2,990 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −590 | $113.84 | $67.17K | 0 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −602 | $112.93 | $67.98K | 590 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −700 | $110.65 | $77.46K | 2,290 |
| Patrice Rioux – | Aug 26, 2026 | Option exercise | +1,380 | $0.01 | $14 | 5,066 |
| Patrice Rioux – | Aug 26, 2026 | Sale(10b5-1 plan) | −1 | $111.26 | $111 | 5,065 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −485 | $108.83 | $52.78K | 11,001 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −590 | $113.84 | $67.17K | 7,396 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −615 | $109.56 | $67.38K | 10,386 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −700 | $110.65 | $77.46K | 9,686 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −1,098 | $111.84 | $122.80K | 8,588 |
| Kim R. Tsuchimoto Director | Aug 26, 2026 | Sale(10b5-1 plan) | −602 | $112.93 | $67.98K | 7,986 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −1,802 | $113.05 | $203.72K | 5,373 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −694 | $110.04 | $76.37K | 7,821 |
| Raymond Anderson Director | Aug 25, 2026 | Option exercise | +1,740 | $30.00 | $52.20K | 8,515 |
| Raymond Anderson Director | Aug 25, 2026 | Option exercise | +1,402 | $30.00 | $42.06K | 6,775 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −646 | $111.07 | $71.75K | 7,175 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −1,802 | $113.05 | $203.72K | 23,751 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −646 | $110.07 | $71.11K | 25,523 |
| Raymond Anderson Director | Aug 25, 2026 | Sale(10b5-1 plan) | −694 | $110.04 | $76.37K | 26,169 |
| Andrew Cittadine Chief Operating Officer | Jun 30, 2026 | Option exercise | +5,254 | – | – | 57,923 |
| Andrew Cittadine Chief Operating Officer | Jun 30, 2026 | Tax withholding | −2,309 | $92.59 | $213.79K | 55,614 |
| Quan Anh Vu Chief Financial Officer | Jun 30, 2026 | Tax withholding | −507 | $92.59 | $46.94K | 2,221 |
| Quan Anh Vu Chief Financial Officer | Jun 30, 2026 | Option exercise | +1,228 | – | – | 2,728 |
| Chandler Robinson Chief Executive Officer, Director | Jun 30, 2026 | Tax withholding | −4,084 | $92.59 | $378.14K | 99,267 |
| Chandler Robinson Chief Executive Officer, Director | Jun 30, 2026 | Option exercise | +12,873 | – | – | 103,351 |
| Andrew Cittadine Chief Operating Officer | Mar 31, 2026 | Option exercise | +3,514 | – | – | 54,240 |
| Andrew Cittadine Chief Operating Officer | Mar 31, 2026 | Tax withholding | −1,571 | $54.79 | $86.08K | 52,669 |
| Chandler Robinson Chief Executive Officer, Director | Mar 31, 2026 | Option exercise | +6,732 | – | – | 92,450 |
| Chandler Robinson Chief Executive Officer, Director | Mar 31, 2026 | Tax withholding | −1,972 | $54.79 | $108.05K | 90,478 |
| Andrew Cittadine Chief Operating Officer | Dec 31, 2025 | Tax withholding | −1,889 | $65.30 | $123.35K | 50,726 |
| Andrew Cittadine Chief Operating Officer | Dec 31, 2025 | Option exercise | +4,326 | – | – | 52,615 |
| Chandler Robinson Chief Executive Officer, Director | Dec 31, 2025 | Tax withholding | −2,558 | $65.30 | $167.04K | 85,718 |
| Chandler Robinson Chief Executive Officer, Director | Dec 31, 2025 | Option exercise | +8,724 | – | – | 88,276 |
| Quan Anh Vu Chief Financial Officer | Dec 26, 2025 | Buy | +1,500 | $69.95 | $104.93K | 1,500 |
| Arthur J. Klausner Director | Dec 18, 2025 | Sale | −461 | $68.09 | $31.39K | 8,762 |
| Arthur J. Klausner Director | Dec 18, 2025 | Sale | −4,660 | $67.06 | $312.50K | 9,223 |
| Diane Hendricks 10% owner | Dec 16, 2025 | Other | −43,499 | – | – | 567,580 |
| Arthur J. Klausner Director | Dec 16, 2025 | Other | +7,710 | – | – | 13,883 |
| Chandler Robinson Chief Executive Officer, Director | Sep 30, 2025 | Tax withholding | −2,646 | $81.67 | $216.10K | 79,552 |
| Chandler Robinson Chief Executive Officer, Director | Sep 30, 2025 | Option exercise | +8,726 | – | – | 82,198 |
| Andrew Cittadine Chief Operating Officer | Sep 30, 2025 | Tax withholding | −1,896 | $81.67 | $154.85K | 48,289 |
| Andrew Cittadine Chief Operating Officer | Sep 30, 2025 | Option exercise | +4,327 | – | – | 50,185 |
| Pharma LLC Tactic Chief Executive Officer, Director, 10% owner | Sep 24, 2025 | Sale | −550,229 | $63.61 | $35.00M | 272,026 |
| Kim R. Tsuchimoto Director | Jul 14, 2025 | Sale | −8,904 | $40.00 | $356.16K | 11,486 |
| Kim R. Tsuchimoto Director | Jul 14, 2025 | Option exercise | +8,904 | $0.01 | $89 | 20,390 |
| Christopher M. Starr Director | Jul 14, 2025 | Option exercise | +16,800 | $0.01 | $168 | 21,973 |
| Christopher M. Starr Director | Jul 14, 2025 | Sale | −16,800 | $40.00 | $672.00K | 5,173 |
| Chandler Robinson Chief Executive Officer, Director | Jul 14, 2025 | Sale | −16,800 | $40.00 | $672.00K | 73,472 |
| Chandler Robinson Chief Executive Officer, Director | Jul 14, 2025 | Option exercise | +16,800 | $0.01 | $168 | 90,272 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Starr Christopher Director | Oct 1, 2026 | 16,800 | $1.34M | Oct 1, 2026 | Exercise of Stock Options |
| Robinson Chandler Director, Officer | Sep 24, 2026 | 29,056 | $2.60M | Sep 24, 2026 | Exercise of Stock Options |
| Rioux Patrice Acting Chief Medical Officer | Aug 26, 2026 | 1 | $111 | Aug 26, 2026 | Exercise of Stock Options |
| Tsuchimoto Kim Director | Aug 26, 2026 | 8,180 | $906.51K | Aug 26, 2026 | Exercise of Stock Options |
| William Anderson Raymond Director | Aug 25, 2026 | 6,284 | $699.79K | Aug 25, 2026 | Exercise of Stock Options |
| Klausner Arthur Former Board Member | Jul 10, 2026 | 5,000 | $476.97K | Jul 8, 2026 | Restricted Stock Unit Vesting |
| Klausner Arthur Employer | Jul 7, 2026 | 5,000 | $485.25K | Jul 7, 2026 | LP in LLC |
| Klausner Arthur Board Member | Dec 19, 2025 | 5,121 | $343.90K | Dec 18, 2025 | LP in LLC |
| Kim R. Tsuchimoto Director | Jul 14, 2025 | 8,904 | $356.16K | Jul 14, 2025 | Stock Option Exercise |
| Chandler Robinson Officer, Director | Jul 14, 2025 | 16,800 | $672.00K | Jul 14, 2025 | Stock Option Exercise |
| Christopher M. Starr Director | Jul 14, 2025 | 16,800 | $672.00K | Jul 14, 2025 | Stock Option Exercise |
| Pharma LLC Tactic 10% Stockholder | Apr 2, 2025 | 33,334 | $1.17M | Apr 2, 2025 | Private Placement |